Background: Status quo (SQ) bias is defined as patient´s tendency to continue taking a previously selected but inferior therapeutic option. Objective: To assess the presence of SQ bias and its associated factors in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: A multicenter, non-interventional study involving 211 patients with RRMS was conducted. Participants answered questions regarding risk preferences and management of simulated MS case-scenarios. The SymptoMScreen (SMSS) questionnaire was used to assess the perception of severity from the patients´perspective. SQ bias was defined as patients' preference to maintain the current treatment despite evidence of disease activity. Mixed linear models adjusting for clustering assessed the association of candidate predictors with the outcome of interest. Results: The mean age (SD) was 39.1 (9.5) years and 70.6% were women. SQ bias was observed in 74.4% (n=161) participants. Univariate analysis showed that SMSS score was associated with SQ bias (OR 1.04; 95% CI 1.01-1.07). Mixed linear regression models suggest that for every point increase in SMSS, there was a 4% increase in the likelihood of SQ bias (β 0.04; 95%CI 0.015-0.06; p<0.002). Among the different symptomatic dimensions included in the SMSS, only vision impairment (β 0.32; 95%CI 0.05-0.50) and depression (β 0.29; 95%CI 0.006-0.58) remained associated with SQ bias in the multivariate analysis. There was no association between participants' risk preferences and SQ bias. Conclusions: Unwillingness to pursue treatments that are more effective is a common phenomenon affecting over 7 out of 10 patients with RRMS. This phenomenon appears to be driven by patients' negative self-perception of their clinical status.Multiple sclerosis (MS) is a chronic autoimmune neurological disorder with a negative impact on patients, their families, and society (Kobelt et al., 2017;García-Domínguez et al., 2019). In recent years, the approval of several new disease modifying therapies (DMT) with different efficacy-risk profiles has added more complexity to the clinical management of MS (Montalban et al., 2018;Saposnik and Montalban, 2018). In this context, there has been a growing interest in patient's views under the paradigm of patient-centered outcomes (Khurana et al., 2017; D´Amico et al., 2019). Establishing treatment goals together with patients is still an unmet need (Yeandle et al., 2018;Day et al., 2018). Shared decision-making emerged as a potential solution, but is hindered by multiple factors, such as physician-patient communication, knowledge gaps regarding therapeutic alternatives, or subjective patient factors not shared with their MS specialists (O´Conor et al., 2007;Kachuck et al., 2011).Therapeutic inertia (TI) is defined as physicians' lack of treatment